Taimei Medical Technologies Raises Over RMB 1.2 Billion Led by Tencent, Hillhouse Capital, and Yunfeng Capital Ahead of IPO Filing

VCBeat (WeChat ID: vcbeat) has learned that on September 28, 2020, Taimei Medical Technology officially announced the completion of a new round of financing totaling over RMB 1.2 billion. The round was led by Tencent, Hillhouse Ventures, and Yunfeng Capital, with participation from Morningside Venture Capital, Matrix Partners China, Zheshang Venture Capital, SoftBank China, Kaifeng Venture Capital, Ivy Capital, Future Qichuang Fund, and Fanzhuo Capital. Fanzhuo Capital served as the exclusive financial advisor.

Meanwhile, Jiaxing Taimei Medical Technology Co., Ltd. (i.e., “Taimei Medical Technology”) was officially renamed Zhejiang Taimei Medical Technology Co., Ltd. on September 11, 2020.

Looking ahead, Taimei will continue to serve as a digital operations platform for the life sciences industry, fully advancing resource integration in innovative drug R&D, the construction and optimization of IT infrastructure, and the expansion of innovative services. By empowering the digitalization and intelligent transformation of new drug development, Taimei is committed to fulfilling its mission of “making quality medicines accessible to all.”

Taimei, adhering to its mission of “making quality medicines accessible,” is building the infrastructure for the future pharmaceutical industry. This initiative aims to accelerate the market launch of new drugs, ensure medication safety for patients, enhance the accessibility of quality medicines, and alleviate the financial burden on patients.

As a digital operations platform for the life sciences industry, Taimei Medical Technology leverages advanced technologies such as cloud computing, mobile internet, big data, and artificial intelligence to independently develop a comprehensive portfolio of professional software products and build a technology-driven professional service system. Its business spans pharmaceutical R&D, pharmacovigilance, medical affairs, market access, and marketing. The company has innovatively created the TrialOS platform, centered on collaboration, which connects hospitals, pharmaceutical companies, service providers, regulatory agencies, patients, payers, and other industry stakeholders. This facilitates extensive resource integration, seamless data flow, and close process collaboration, while unifying industry standards, thereby driving value enhancement and win-win outcomes across the industry.